Bridging Preclinical Science And Trial Supply Success

By Joseph G. Oberlander, Ph.D., PMP, pharmaceutical development consultant and program manager

The journey from early scientific discovery to a successful clinical trial is one of the most intricate transitions in modern pharmaceutical drug development. Preclinical scientists work at the frontiers of biology and medicine, exploring mechanisms, refining formulations, and generating the data needed to advance a candidate molecule or device toward human studies. Meanwhile, clinical supply teams are responsible for transforming the scientific promises of these candidate treatments into tangible, compliant, and reliable products that can be delivered to trial sites around the world. Despite their shared mission, these two groups often operate in separate spheres or silos. Their priorities differ, their timelines rarely align, and their communication channels can be fragmented. This disconnect can lead to costly delays, inefficient use of drug substance or prototype devices, and even jeopardize patient enrollment and sound statistical evaluation of the benefits of the therapies. As investigational therapies grow more complex and development timelines accelerate, bridging the gap between preclinical science and clinical trial supply is no longer optional — it is essential to the success of modern drug development.

Why Does The Gap persist?  

Preclinical research is inherently exploratory: scientists and engineers iterate rapidly, adjusting formulations, dosing assumptions, delivery mechanisms, or device designs as new data emerges from limited models (animal or simulation). This agile approach is extremely effective for generating new ideas but less practical for application of these ideas to real-world therapies. Clinical supply experts, by contrast, depend on predictability and a larger degree of certainty of the product. Clinical trials operate in an environment that requires firm decisions and documented specifications, and long‑range planning requires a large degree of stability from clinical supply experts. When one function thrives on flexibility and the other on stability, friction is inevitable.

Uncertainty in early development compounds this challenge. Dose ranges may still be evolving when supply teams need to begin forecasting. Stability data (and shelf-life estimations) may be incomplete when packaging decisions must be made, resulting in having to plan for repeat work. Materials of construction for devices and compatibility with chemical components may be in flux and not widely available in markets for trial, complicating sourcing efforts. Even the route of administration can shift late in the process, forcing supply teams to rework plans that were already in motion. Some organizational structures can exacerbate these divides. Many companies, especially smaller and newer biotechs, place preclinical research within R&D and clinical supply within clinical operations or in manufacturing, creating natural silos. Without intentional collaboration, critical information flows slowly — or not at all.

Why Bridging The Gap Matters More Than Ever

The consequences of misalignment have never been higher. The rise of complex modalities such as cell and gene therapies, mRNA platforms, and targeted biologics has introduced new layers of logistical and regulatory complexity as these products often require ultra‑cold storage, specialized packaging, and rigorous chain‑of‑identity controls. Medical device/drug combination products or combination drug therapies exponentially increase the complexity of inventory management. The global reach of planned trials adds further complexity. Each country has its own labeling rules, import requirements, and distribution constraints, including the availability of various materials in medical devices. Early scientific decisions, such as formulation, packaging configuration, or material for ancillary devices, can have major downstream implications for global feasibility.

At the same time, accelerated regulatory pathways compress development timelines. When a program receives Fast Track or Breakthrough Therapy designation, the entire organization must move faster, as a supply delay that might once have been manageable can now derail a program’s momentum. Finally, patient‑centric trial designs, including decentralized trials and direct‑to‑patient shipments, require supply chains that are flexible, responsive, and deeply informed by the science behind the product. Without alignment, these modern trial models become difficult to execute.

Strategies To Bridge the Gap

Bridging the divide between preclinical science and clinical supply requires more than occasional cross‑functional meetings: It demands a fundamental shift in how organizations think, plan, and collaborate. The following strategies offer a comprehensive framework for creating a more integrated, resilient, and science‑driven approach to clinical trial supply.

1. Bring Supply Chain Thinking Into Early Development: One of the most transformative steps an organization can take is to involve supply chain experts from the earliest stages of development. Instead of waiting for a formal handoff, supply professionals should be present during discussions about formulation feasibility, stability, study design, and dose‑range exploration. Their insights help ensure that scientific decisions are evaluated not only for their biological merit but also for their manufacturability, scalability, and distribution implications. These early feasibility assessments can be particularly powerful. By evaluating cold chain requirements, packaging constraints, materials of construction, labeling considerations, and global distribution challenges before a drug candidate or device even enters IND‑enabling studies, teams can avoid late‑stage surprises that lead to rework or delays. This early alignment also enables the creation of a “minimum viable supply strategy” — a flexible plan that evolves as scientific data matures but provides enough structure to support early forecasting and planning.

2. Build Cross‑Functional Governance and Communication Frameworks: Collaboration does not happen organically; it must be designed into the development process. Integrated development teams that include preclinical scientists, CMC leads, clinical operations, quality, regulatory, and clinical supply professionals create a shared forum for decision‑making. These teams meet regularly, share updates, and jointly assess risks, ensuring that no function is operating in isolation. Stage‑gate reviews can also play a critical role by incorporating supply‑related criteria into each development milestone, such as readiness of stability data, clarity on dose strengths, or understanding of global labeling requirements. Organizations can ensure that supply readiness is evaluated alongside scientific progress; shared KPIs further reinforce alignment by giving teams common goals, whether that’s reducing waste, accelerating time‑to‑first‑patient, or minimizing supply‑related deviations.

3. Use Scenario Planning and Predictive Modeling to Manage Uncertainty: Uncertainty is unavoidable in early development, but it can be managed through thoughtful scenario planning. Instead of relying on a single forecast, supply teams can model multiple dosing regimens, enrollment curves, and regional variations. This allows them to prepare for a range of possibilities without committing prematurely to a single plan. Predictive modeling tools can simulate packaging configurations, label layouts, and temperature‑sensitive shipping requirements, helping teams choose designs that maximize flexibility and minimize rework. Machine learning models can also be employed to forecast inventory needs, expiry risks, and site‑level consumption patterns, enabling more efficient use of drug substance or device prototypes — particularly valuable for expensive or scarce materials or designs.

4. Invest in Digital Integration and Data Connectivity: Data silos are one of the biggest barriers to alignment. When R&D, CMC, manufacturing, quality, and supply chain systems operate independently, information moves slowly and inconsistently. A unified digital ecosystem creates a single source of truth that supports faster, more informed decision‑making. Digital twins — virtual models of manufacturing processes, stability profiles, or distribution routes — allow teams to test supply strategies before committing resources. Real‑time dashboards that track inventory levels, batch release status, and shipment progress give teams the visibility they need to respond quickly to emerging risks. These tools not only improve operational efficiency but also strengthen trust between scientific and supply teams.

5. Foster a Culture of Collaboration and Shared Ownership: Technology and process improvements are powerful, but culture is the glue that holds everything together. Teams must feel empowered to communicate openly, raise concerns early, and view challenges as shared responsibilities rather than functional boundaries. Cross‑training can help build mutual understanding. When scientists understand the constraints of materials of construction and excipient differences between jurisdictions, packaging, labeling, and distribution, they make more supply‑aware decisions. When supply teams understand the scientific uncertainty inherent in early development, they plan with greater flexibility and empathy. Celebrating joint successes reinforces the idea that scientific and supply achievements are inseparable.

6. Design Flexible, Modular Supply Chains: Flexibility is essential in early development, where scientific assumptions can shift rapidly. Modular packaging designs or materials substitutions, adaptable label templates, and just‑in‑time labeling approaches allow teams to incorporate late‑breaking scientific or regulatory changes without delaying shipments. Securing redundant manufacturing capacity or establishing dual‑sourcing strategies can further reduce risk, ensuring that supply continuity is maintained even when unexpected challenges arise.

7. Strengthen Regulatory Foresight and Global Readiness: Regulatory complexity is a major source of supply delays, particularly in global trials. Mapping global requirements early — before trial sites are activated — helps teams anticipate challenges related to labeling, import/export restrictions, cold chain documentation, and local language requirements. Proactive engagement with regulators can clarify expectations and reduce the risk of supply‑related findings during inspections or submissions.

Conclusion

Bridging preclinical science and trial supply success is not a single initiative but a holistic transformation. It requires new ways of working, new technologies, and a cultural shift toward shared ownership of development outcomes. When scientific insight and supply chain execution move in harmony, organizations accelerate timelines, reduce risk, and deliver investigational therapies to patients with greater reliability and confidence. The future of drug and medical device development belongs to companies that treat supply strategy as an extension of scientific strategy. When these two worlds operate as one, innovation reaches patients faster and with far greater impact.

About The Author:

Joseph G. Oberlander, Ph.D., PMP, is an experienced pharmaceutical development consultant and program manager. His consulting experience ranges from preclinical to Phase 3 programs, across multiple therapeutic areas (oncologic, metabolic, CNS) and drug modalities (NCE, biologics, biosimilars, generics, CGT), at clients ranging from virtual startups to large biopharma, and throughout the drug life cycle (from raw materials sourcing to finished goods use) for drug programs with global operations. His consulting focus includes deep expertise in clinical supply chain strategy and distribution logistics and in analytical and stability program management. In addition, he has significant research experience in neurobiology and is a published author contributing to the understanding of inherent biological sex differences in synaptic physiology and how these differences impact drug effects and deepen our understanding of preclinical disease models.